Fox Christine
SEC CIK 1998173 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | EVP, U.S. Commercial | 63.6K | — | $3.17M | 12 | 2024-11-20 | 2026-04-30 |
Most active insiders at TEVA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Francis Richard D | Pres, CEO | — | $31.26M |
| 2 | MIGNONE ROBERTO | Dir | — | $22.82M |
| 3 | Kalif Eliyahu Sharon | EVP, CFO | — | $20.72M |
| 4 | Sabag Mark | See "Remarks" | — | $13.15M |
| 5 | Daniell Richard | EVP, European Commercial | — | $12.08M |
| 6 | Hughes Eric A | See "Remarks" | — | $4.17M |
| 7 | Fox Christine | EVP, U.S. Commercial | — | $2.75M |
| 8 | Lippman Evan | EVP, Business Development | — | $2.16M |
| 9 | Weiss Amir | CAO | — | $1.41M |
| 10 | Shields Matthew | EVP, Gbl Ops | — | $1.40M |
Transactions 12
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 16:00 | 2026-04-30 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, U.S. Commercial | S - Sale | $35.31 | -21.3K | 63.6K | -25% | -$750.6K | |
| DT | 2026-03-09 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, U.S. Commercial | S - Sale+OE | $31.67 | -7,924 | 84.9K | -9% | -$251.0K |
| DT | 2026-03-09 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, U.S. Commercial | M - OptEx | — | +17.8K | 92.8K | +24% | — |
| DT | 2026-03-06 | 2026-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, U.S. Commercial | M - OptEx | — | +20.5K | 84.1K | +32% | — |
| DT | 2026-03-06 | 2026-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, U.S. Commercial | S - Sale+OE | $32.46 | -9,098 | 75.0K | -11% | -$295.3K |
| DT | 2025-11-24 | 2025-11-20 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, Head of U.S. Commercial | S - Sale+OE | $24.78 | -28.2K | 63.6K | -31% | -$699.5K |
| DT | 2025-11-24 | 2025-11-20 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, Head of U.S. Commercial | M - OptEx | — | +63.5K | 91.9K | +224% | — |
| 2025-11-18 | 2025-11-14 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, Head of U.S. Commercial | S - Sale | $25.11 | -30.0K | 28.4K | -51% | -$753.3K | |
| DMT | 2025-03-06 | 2025-03-04+ | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, Head of U.S. Commercial | S - Sale+OE | $15.79 | -6,181 | 60.5K | -9% | -$97.6K |
| DT | 2025-03-06 | 2025-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, Head of U.S. Commercial | M - OptEx | — | +20.5K | 64.6K | +46% | — |
| DT | 2024-11-21 | 2024-11-20 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, Head of U.S. Commercial | S - Sale+OE | $16.87 | -19.4K | 44.1K | -31% | -$327.1K |
| DT | 2024-11-21 | 2024-11-20 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | EVP, Head of U.S. Commercial | M - OptEx | — | +63.5K | 63.5K | New | — |
Purchase Sale Sale after option exercise All abbreviations